Is Hemolytic-uremic Syndrome hereditary?

Hemolytic-uremic syndrome (HUS) is not a single disease but a clinical syndrome that can be triggered by either infection or underlying genetic factors. While typical HUS (STEC-HUS) is caused by bacterial toxins and is not hereditary, atypical hemolytic-uremic syndrome (aHUS) is frequently caused by genetic mutations in the complement system, making it a hereditary condition in many cases.

Is Hemolytic-uremic syndrome hereditary?

Whether Hemolytic-uremic syndrome is hereditary depends entirely on the subtype. The most common form, often referred to as typical HUS, is triggered by Shiga toxin-producing E. coli (STEC) and is not inherited. However, atypical Hemolytic-uremic syndrome (aHUS) is a rare, life-threatening condition characterized by chronic, uncontrolled activation of the alternative complement pathway. In approximately 50% to 60% of patients with aHUS, a specific genetic mutation can be identified, meaning the condition is hereditary and can be passed through families.

What are the inheritance patterns of atypical Hemolytic-uremic syndrome?

When Hemolytic-uremic syndrome is caused by genetic mutations, it most commonly follows an autosomal dominant inheritance pattern, though autosomal recessive patterns occur. This means that an affected parent has a 50% chance of passing the mutation to each child. However, it is crucial to understand the concept of "incomplete penetrance." Many individuals carry the genetic predisposition for Hemolytic-uremic syndrome but may never develop symptoms unless a secondary trigger—such as a viral infection, pregnancy, or surgery—activates the complement system.

When is genetic testing recommended for Hemolytic-uremic syndrome?

Genetic testing is a cornerstone in the management of patients suspected of having aHUS. Clinical geneticists recommend testing in the following scenarios:

• When there is no evidence of a Shiga toxin-producing bacterial infection.


• When a patient presents with recurrent episodes of Hemolytic-uremic syndrome.


• When there is a positive family history of thrombotic microangiopathy (TMA).


• To guide treatment decisions, as genetic information helps determine the efficacy of complement-inhibitor therapies.


• For family planning, to identify at-risk relatives who may be asymptomatic carriers.

Are de novo mutations common in this condition?

Yes, de novo (spontaneous) mutations are observed in cases of Hemolytic-uremic syndrome. A de novo mutation occurs when the genetic change is present for the first time in the affected individual and was not inherited from either parent. Because of the complex, multifactorial nature of the complement system, genetic counseling is essential to interpret whether a mutation is inherited or a new occurrence, and to assess the risk of recurrence in future siblings.

What is the role of genetic counseling?

Genetic counseling provides families with a clear understanding of the risks associated with Hemolytic-uremic syndrome. A counselor can help map the family history, explain the likelihood of incomplete penetrance, and discuss carrier testing for family members. For those planning a pregnancy, counseling is vital because pregnancy itself is a known trigger for aHUS, and monitoring protocols can be established to ensure maternal and fetal safety.

Next steps

• Consult with a nephrologist or a hematologist specializing in complement-mediated diseases.


• Request a referral to a clinical geneticist for comprehensive genetic testing and counseling.


• Connect with the 93 other community members at DiseaseMaps.org to share experiences and find support.


• Monitor for early warning signs if you are a known carrier, especially during periods of physiological stress or infection.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Atypical hemolytic-uremic syndrome.


• Orphanet: Atypical hemolytic-uremic syndrome (ORPHA: 3262).


• OMIM (Online Mendelian Inheritance in Man): Complement Factor H Deficiency and related complement-mediated TMA.


• The Atypical HUS Foundation: Resources for patients and families.